in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
188 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog<br />
❚ arachidonic acid metabolite secretion<br />
PGI 2 secretion<br />
cellul ar<br />
Ref. 0240 Activator effect<br />
Ref. 0241 Inhibitor effect<br />
[CUSTOM OFFER]<br />
Source<br />
TXB 2 secretion (<strong>in</strong>hibitor effect)<br />
cellul ar<br />
Ref. 2006<br />
[CUSTOM OFFER]<br />
HUV-EC-C<br />
Measured product 6ketoPGF 1α<br />
Detection method EIA<br />
Activator effect Control thromb<strong>in</strong> (0.3 U/mL)<br />
Reference thromb<strong>in</strong> (EC 50 : 0.04 U/mL)<br />
Inhibitor effect Stimulant human thromb<strong>in</strong> (0.3 U/mL)<br />
Reference <strong>in</strong>domethac<strong>in</strong> (IC 50 : 8.6 nM)<br />
Zavoico, G.B. et al. (1989) J. Immunol., 142: 3993-3999.<br />
❚ This model should be used to test pro-<strong>in</strong>flammatory drugs.<br />
Source<br />
differentiated HL-60<br />
Stimulant<br />
A23187 (5 µM)<br />
Measured product TXB 2<br />
Detection method EIA<br />
Reference<br />
<strong>in</strong>domethac<strong>in</strong> (IC 50 : 4.7 nM)<br />
[Solvent] must be kept ≤ 0.1%<br />
Zaitsu, M. et al. (2002) Prost. Leuk. Essent. Fatty Acids, 67: 405-410.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.1%<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
❚ Chemok<strong>in</strong>e secretion<br />
IL-8 secretion (<strong>in</strong>hibitor effect)<br />
cellul ar<br />
Ref. 0272<br />
[CUSTOM OFFER]<br />
Source<br />
PBMC<br />
Stimulant<br />
LPS (1 µg/mL)<br />
Measured product IL-8<br />
Detection method EIA<br />
Reference<br />
dexamethasone (IC 50 : 8.4 nM)<br />
[Solvent] must be kept ≤ 0.1%<br />
Sch<strong>in</strong>dler, R. et al. (1990) Blood, 75: 40-47.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
❚ Cytok<strong>in</strong>e secretion<br />
IFN-g secretion (<strong>in</strong>hibitor effect)<br />
cellul ar<br />
Ref. 0368<br />
[CUSTOM OFFER]<br />
Source<br />
Stimulant<br />
Measured product<br />
PBMC<br />
PHA (2 µg/mL)<br />
IFN-γ<br />
Detection method EIA<br />
Reference<br />
dexamethasone (IC 50 : 3.5 nM)<br />
[Solvent] must be kept ≤ 0.1%<br />
Andre, F. et al. (1996) Allergy, 51: 350-355.<br />
IFN-γ secretion (% of control)<br />
100<br />
50<br />
0<br />
-10 -9 -8 -7 -6 -5<br />
log [drug] (M)<br />
dexamethasone<br />
IL-1β secretion (<strong>in</strong>hibitor effect)<br />
cellul ar<br />
Ref. 0262<br />
[CUSTOM OFFER]<br />
Source<br />
Stimulant<br />
Measured product<br />
PBMC<br />
LPS (1 µg/mL)<br />
IL-1β<br />
Detection method EIA<br />
Reference<br />
cycloheximide (IC 50 : 230 nM)<br />
[Solvent] must be kept ≤ 0.1%<br />
Sch<strong>in</strong>dler, R. et al. (1990) Blood, 75: 40-47.<br />
IL-1β secretion (% of control)<br />
100<br />
50<br />
0<br />
-9 -8 -7 -6 -5<br />
log [drug] (M)<br />
cycloheximide
Change language